Drug intelligence / Profile preview

CDVAX

Development stage: Phase 1
Lead developer: Royal Holloway University of London
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

CDVAX is an investigational oral vaccine designed to prevent Clostridium difficile infection (CDI). It consists of recombinant spores of Bacillus subtilis engineered to display a fragment of C. difficile toxin A (TcdA26-39) on their surface. The vaccine is administered orally and aims to induce both mucosal and systemic immune responses, providing protection against colonization by C. difficile as well as neutralizing its toxins. Preclinical studies demonstrated efficacy in animal models, protecting against primary infection and relapse with various virulent strains of C. difficile. The vaccine was developed through a European consortium led by Royal Holloway University of London, with contributions from several biotech SMEs for regulatory support, manufacturing, analytics, and clinical supervision[3].

Brand names: CDVAX
Other names: CD-VAX

Targets

TcdA26-39 (Clostridioides difficile toxin A N-terminal epitope (residues 26-39))

Beyond the preview

Go deeper on CDVAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDVAX.

Explore the full profile